Loading clinical trials...
Loading clinical trials...
A Phase I/II Study of the Safety, Immunogenicity, and Efficacy of Sm-TSP-2/Alhydrogel® With or Without AP 10-701 for Intestinal Schistosomiasis in Healthy Ugandan Adults
Conditions
Interventions
Sm-TSP-2/Alhydrogel® vaccine
Sm-TSP-2/Alhydrogel® vaccine plus AP 10-701
+1 more
Locations
1
Uganda
Makerere University Walter Reed Project
Kampala, Uganda
Start Date
October 7, 2019
Primary Completion Date
November 13, 2024
Completion Date
November 13, 2024
Last Updated
November 4, 2025
NCT07484256
NCT06311344
NCT07482215
NCT06312462
NCT05292391
NCT06828536
Lead Sponsor
Baylor College of Medicine
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions